Targets › PDGF
1 program from 1 company in 1 trial: 1 Phase 1; Gastroenterology; next expected readout Jun 2027.
Open in Phaseline: the race on PDGF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Nova Southeastern University | recombinant human platelet derived growth factor (GEM-21) recombinant human PDGF for bone regeneration | PDGF | Phase 1 | Intrabony Periodontal Defect | Jun 2027 |
Intrabony Periodontal Defect (1)
protein or peptide (1)
Nova Southeastern University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.